I don't see any mystery with the current SP. The company's own forecast is that p3 data is 3 years away, registration and revenue at least 4. And if the FDA stick to their guns and require a confirmatory trial it would require another CR and push the timeline out even more. Too many investors now have a short-term mentality. Money will return if FDA agrees to single p3 trial and if trial starts on schedule, but not before.
Ann: Ceasing to be a substantial holder, page-51
-
- There are more pages in this discussion • 2 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
